THE ROLE OF DRUGS OF BIOLOGICAL ORIGIN IN COMBINED THERAPY AND PREVENTION OF THE CHRONIC PROSTATITIS
Keywords:
chronic prostatitis, chronic pelvic pain syndrome, drug treatment, drugs of biological origin.Abstract
Introduction. Chronic prostatitis affects 10-15% of the male population of developed countries, resulting in 2 million or more outpatient visits to the doctor, while the recurrence rate increases with the age of the patient up to 50%. Standard complex therapy in most cases does not lead to a decrease in the number of relapses.
Purpose of the study. The efficacy of drugs of biological origin (Adenoprosin®) in combined therapy and prevention of chronic prostatitis was evaluated.
Material and methods. Using the unified protocol from 2021 to 2022 2907 men were selected with a diagnosis of chronic prostatitis category II, III according to the NIH criteria, as well as patients with chronic prostatitis (CP) and benign prostatic hyperplasia (BPH). All patients received complex therapy and additional therapy with the drugs of biological origin in the form of rectal suppositories 150 mg once a day for 30 days.
Results and discussion. When analyzing the Chronic Prostatitis Symptom Summary Questionnaire (NIH-CPSI) questionnaire during the follow-up survey, moderate symptoms were observed in 17% of patients (50% before treatment), and severe symptoms were observed in 16.2% of patients (48% before treatment). In patients with CP of category II and III and patients with CP with concomitant BPH, the results of NIH-CPSI have turned out as similar; according to the results of the assessment of indicators of the International Prostate Symptom Scale (IPSS), there was a steady decrease from 19.2±1.9 to 6.2±1.9 points.
Conclusions. As the result of the inclusion of the drug of biological origin to the complex therapy of patients with CP II, III categories and patients with CP and BPH is therapeutically justified, a positive result was obtained in 83.8% of cases.
References
1. Kunishima Y, Mori M. Kitamura H, Satoh H., Tsukamoto T. Prevalence of prostatitis-like symptoms in Japanese men: population-based study in a town in Hokkaido. Int J Urol. 2006;13 (10):1286–1289. doi:10.1111/j.1442-2042.2004.01556.x
2. Giacomo MP, Tiziano V, Stefano R, Filippo A, et al. Chronic prostatitis: current treatment options. Res Rep Urol. 2019; 4(11):165-174. doi: 10.2147/RRU.S194679
3. Vittorio M, Matteo B, Tommaso C, Rober C, et al. Multidisciplinary approach to prostatitis. Arch Ital Urol Androl. 2019;18;90(4):227-248. doi: 10.4081/aiua.2018.4.227
4. Krupin VN, Krupin AV, Belova AN. Chronic prostatitis / chronic pelvic pain: what do we treat? Consilium Medicum. 2019;21(7):42–48. doi.org/10.26442/20751753.2019.7.190388. (In Russ.)
5. Apolikhin OI, Sivkov AV, Komarova VA, Nikushina AA. Diseases of the prostate gland in the Russian Federation statistical data. Eksperimentalnaia i klinicheskaia urologiia = Experimental and clinical urology. 2019;2:4-12 doi: 10.29188/2222-8543-2019-11-2-4-12. (In Russ.)
6. Jun SK, Hyo JK, Sheng-Min W, Kang JC, et al. Depression and Somatic Symptoms May Influence on Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Preliminary Study. Psychiatry Investig. 2014;11(4):495-498. doi: 10.4306/pi.2014.11.4.495 PMCID: PMC4225217
7. Alchinbayev MK, Aryngazina AM, Muhamedzhan I. Men’s health in the republic of Kazakhstan. Meditsina (Almaty) = Medicine (Almaty). 2014;12:27-32. (In Kazakhstan)
8. Kulchavenia EV, Kholtobin DP, Shevchenko SIu, et al. Chastota khronicheskogo prostatita v strukture ambulatornogo urologicheskogo priema. Eksperiment. i klin. Urologiia = Experimental and clinical urology. 2015; 1: 16–8. (In Russ.)
9. Lei Z, Yi W, Zhiqiang Q, Xian G, et al. Correlation between Prostatitis, Benign Prostatic Hyperplasia and Prostate Cancer: A systematic review and Meta-analysis. Journal of Cancer. 2020;11(1):177-189. doi: 10.7150/jca.37235
10. Sugimoto M, Hijikata Y, Tohi Y. et al. Low quality of life in men with chronic prostatitis-like symptoms. Prostate Cancer Prostatic Dis. 2022;25:785–790. https://doi.org/10.1038/s41391-022-00559-w
11. Krieger JN, Nyberg LJr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999;282:236–7. https://doi.org/10.1001/jama.282.3.236
12. Kim SH, Ha US, Yoon BI, Kim SW, et al. Microbiological and clinical characteristics in acute bacterial prostatitis according to lower urinary tract manipulation procedure. J Infect Chemother. 2014;20:38-42. doi: 10.1016/j.jiac.2013.11.004
13. Krieger JN, Thumbikat P. Bacterial Prostatitis: Bacterial Virulence, Clinical Outcomes, and New Directions. Microbiol Spectr. 2016;4(1):1-11. doi: 10.1128/microbiolspec.UTI-0004-2012
14. Khan FU, Ihsan AU, Nawaz W, Khan MZ, et al. A novel mouse model of chronic prostatitis/chronic pelvic pain syndrome induced by immunization of special peptide fragment with aluminum hydroxide adjuvant. Immunol Lett. 2017;187: 61-67. doi: 10.1016/j.imlet.2017.05.008
15. Khan FU, Ihsan AU, Khan HU, Jana R, et al. Comprehensive overview of prostatitis: a systematic review. Bio. Pharm. 2017;94:1064–1076. doi: 10.1016/j.biopha.2017.08.016
16. Tiktinsky OL, Kalinina SN, Mikhailichenko VV. Andrology. Мoscow: LLC "Med. inform. agency”; 2010:576.
17. Kogan MI, Naboka YL, Ismailov RS, Belousov II, Gudima IA. Bacterial prostatitis: epidemiology and etiology. Urology. 2018;6:144-148. doi: https://dx.doi.org/10.18565/urology.2018.6.144-148. (In Russ.)
18. Klotz SGR, Ketels G, Lowe B, Brunahl CA. Myofascial findings and psychopathological factors in patients with chronic pelvic pain syndrome. Pain Med. 2020;21:34–44. https://doi.org/10.1093/pm/pny097
19. Almugbel SK, Alanezi FKB, Alhoshan FM, Alkhalifa RO, et al. Classification and treatment of prostatitis: a review of literature. Int J Community Med Public Health. 2018;5:4941–6. https://doi.org/10.18203/2394-6040.ijcmph20184247
20. Juan VF, Tarek T, Jae HJ, Yu-Tian X, et al. Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database Syst Rev. 2018;12;5(5):180. doi: 10.1002/14651858.CD012551.pub3
21. Doiron RC, Tripp DA, Tolls V, Nickel JC. The evolving clinical picture of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a look at 1310 patients over 16 years. Can Urol Assoc J. 2018;12:196–202. https://doi.org/10.5489/cuaj.4876
22. Franco JVA, Turk T, Jung JH, Xiao YT, Iakhno S, Tirapegui FI, et al.. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review. BJU Int. 2020;125:490–6. https://doi.org/10.1111/bju.14988
23. Engeler D, Baranowski AP, Borovicka AM, Dinis-Oliveriea P, Elneil S, Hughes J, et al. EAU guidelines on chronic pelvic pain. European Association of Urology; 2021. Arnhem: EAU Guidelines Office. Available from: http://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Chronic-Pelvic-Pa.
24. Arthur SL, Lees VN, Aquina LYW, Mandy M, Michael G. Psychological management of patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a systematic review. Scand J Pain. 2022;9;23(1):25-39. doi: 10.1515/sjpain-2022-0049
25. Katibov MI. Alibekov MM. Modern approaches to the treatment of chronic bacterial prostatitis. Eksperimentalnaia i klinicheskaia urologiia = Experimental and Clinical Urology. 2022;15(2):130-139. https://doi.org/10.29188/2222-8543-2022-15-2-130-13. (In Russ.)
26. Kadyrov ZA, Stepanov VS, Faniev MV. Possibilities of entomological drugs in the symptomatic and pathogenetic therapy of benign prostatic hyperplasia and chronic abacterial prostatitis. Andrologiia i genitalnaia khirurgiia = Andrology and Genital Surgery. 2020;21(3):69-74. https://doi.org/10.17650/2070-9781-2020-21-3-69-74. (In Russ.)
27. Entomotherapy is a new trend in urology. Effektivnaia farmakoterapiia = Effective pharmacotherapy. 2020;16(3):40-44. (In Russ.)
28. Kuzmenko AV, Kuzmenko VV, Gyaurgiev .A. Entomological drug adenosine for the treatment of patients with benign prostatic hyperplasia and chronic prostatitis. Urologiia = Urology. 2021;1:39-44. doi: 10.18565/urology.2021.1.39-44. (In Russ.)
29. Al-Shukri AS, Kostyukov SV, Maksimova AV. Effcacy evaluation of entomological drug Adenoprosin® usage in combined treatment of patients with lower urinary tract symptoms due to benign prostate enlargement. Urologicheskie vedomosti = Urology reports (St. Petersburg). 2021;11(4):337-344. DOI: https://doi.org/10.17816/uroved89410. (In Russ.)
